Atelerix and Rodon Global partner to integrate cryo-free preservation technology into specialist logistics solutions
Initial agreement to incorporate Atelerix’s non-cryogenic cell preservation technology into international freight and logistics services for drug discovery and clinical trialsPartnership showcased at SACRA (South African Clinical Research Association), Pretoria, 1–2 Oct
TRIMTECH Therapeutics establishes Scientific Advisory Board
Targeted protein degradation experts Prof.
Qureight appoints Craig Rhodes as Head of Partnerships to lead on pharma relationship management
Appointment underscores Qureight’s commitment to drive adoption of its AI-powered imaging and clinical data curation platform to support clinical trials and accelerate drug development timelines for lung and heart diseasesFormer big tech executive and NVIDIA director wi
Qureight’s AI 3D imaging platform to support Calluna Pharma’s Phase 2 AURORA study of CAL101 in Idiopathic Pulmonary Fibrosis (IPF)
Qureight’s advanced AI 3D imaging platform to be used across clinical trial to evaluate anatomical lung changes in adult patients, including during patient enrolmentCAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream
Bio-Rad expands range of StarBright Dyes to enhance panel design capabilities for Spectral Flow Cytometry
New Range of StarBright™ Dyes Developed Specifically for Spectral Flow Cytometry Provide Greater Flexibility in Immunology Research
Bio-Rad Launches EZ-Check Salmonella spp. Kit for Detection of Salmonella spp. in Food and Environmental Samples
Kit Approved by AOAC International and certified NF VALIDATION by AFNOR Certification
Camena Bioscience and Constructive Bio join synthetic biology collaboration to develop plant genomics
Project backed by £9.1m funding from ARIA, the Advanced Research + Invention Agency, to develop synthetic chloroplast genomesProject is led by the Max-Planck Institute of Molecular Plant Physiology and also includes academics from University of Essex a
Sunil Shah and Dr Catherine Elton join Atelerix’s Board to drive global commercial expansion
Industry leaders Sunil Shah (CEO, o2h Ventures) and Dr Catherine Elton (CBO, Axol Bioscience) appointed as Chair and Non-Executive Director, respectively
Antibodies.com expands UK headquarters with new 5x larger facilities in Cambridge to accommodate rapid growth
Cambridge, UK, 04 August 2025: Antibodies.com, a trusted provider of high-quality biological reagents for life science researchers, today announced the expansion of its UK headquarters with a move to Cambridge Technopark to accommodate the Company’
Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials
CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidateCentauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in human clinical study in early 2026
Exonate plans ‘CLEAR-DE’ Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedemaPhase IIb trial to investigate efficacy in NPDR patients to commence in Q1 2026
PhoreMost appoints Dr Adam Gilbert to Scientific Advisory Board
Expert in targeted protein degradation and drug discovery will support development of the Company’s portfolio of novel small molecule degraders
PhoreMost demonstrates new approach to rationalise molecular glue drug discovery
Breakthrough data validates capabilities of GlueSEEKER platform to identify novel induced protein-protein interactions and expand druggable space
Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion
Cambridge, UK – 15 July 2025 – Qureight, a techbio company accelerating drug development using its proprietary deep-learning image biomarkers and clinical data analytics platform, today announced the first results from a collaboration with Insilico Medicine (“Insilico”), a clinic
OMED Health launches new gastrointestinal treatments and services through personalized health plans
OMED Health (“OMED”), a UK-based business pioneering non-invasive breath analysis for gut health and part of Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the launch of OMED He
SPT Labtech and Semarion collaborate to advance automated cell-based assay workflows
SPT Labtech, a global leader in innovative laboratory automation, today announced a strategic collaboration with Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs.
Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer
Centauri Therapeutics Limited (‘Centauri’ or ‘the Company’), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the appointment of Dr.
Optibrium secures multi-million-pound financing package from Shawbrook to accelerate business growth
Optibrium, a leading developer of software and AI solutions for molecular design, today (8 July 2025) announced it has secured a strategic financing package with Shawbrook, a specialist UK bank that provides finance to established UK businesses on high growth trajectories.
Bio-Rad expands Droplet Digital PCR offering through strategic acquisition and platform rollout
HERCULES, Calif. — July 7, 2025 — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announces the launch of four new Droplet Digital™ PCR (ddPCR™) platforms.
Optibrium partners with TalTech on EU-Funded PhD Programme to advance sustainable drug discovery
The research will focus on developing faster and more accurate methods for predicting drug metabolism
Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery
Study identifies new metrics to enhance scRNA-seq based virtual cell modellingFoundational paper to drive development of improved virtual cell models for rejuvenation target discoveryCambr
4basebio introduces new branding to reflect next phase of growth enabling development of advanced genetic therapies
4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today (01 July 2025) announced refreshed branding and the launch of its new website, reflecting the company’s continued growth and success in this rapidly advancing field.
Zyme Communications celebrates 15 years of providing specialist support for the life science sector
Zyme Communications Ltd. (Zyme), the life science specialist PR and marketing agency, today (26 June 2025) celebrates its 15-year anniversary, and introduces refreshed branding to reflect this milestone and the Company’s continued development.
Enhanced Genomics and The ALBORADA Drug Discovery Institute partner to accelerate Alzheimer's drug discovery
Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of
